Positive trial results for PYC’s eye disease therapies
PYC Therapeutics (ASX:PYC) has announced significant progress in its efforts to develop RNA-based precision medicines for genetic diseases.
Read MoreTag: PYC
PYC Therapeutics earns FDA orphan drug designation for RP11 therapy
PYC Therapeutics (ASX:PYC) has received Orphan Drug Designation from the US Food and Drug Administration for its drug candidate VP-001, aimed at treating Retinitis Pigmentosa type 11.
Read MoreStocks of the Hour: PYC Therapeutics, Caprice Resources, Walkabout Resources
A snapshot of the stocks on the move, featuring PYC Therapeutics (ASX:PYC), Caprice Resources (ASX:CRS) and Walkabout Resources (ASX:WKT).
Read More
